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New-onset hyperglycemia: a potential  
clue to detect early pancreatic cancer 
ABSTRACT
Pancreatic adenocarcinoma has an incidence rate 
nearly equal to the mortality rate and this is mostly 
due to late onset of symptoms and delay in diagnosis. 
Early diagnosis of this cancer gives the opportunity 
for total resection of pancreas and creates hope for 
a full recovery. Compelling evidence now indicates that 
new-onset diabetes may be a manifestation of occult 
pancreatic carcinoma. Authors report a young female 
who presented with new-onset severe hyperglycemia 
and superficial thrombophlebitis. She was subse-
quently diagnosed with pancreatic cancer confirmed 
by histopathology. Her glycemic status evaluated 
6 months prior to her presentation during institutional 
health check-up was entirely normal. This case report 
will serve to emphasize that new-onset diabetes in 
certain patients could be a presenting feature of 
pancreatic cancer. (Clin Diabetol 2017; 6, 3: 115–117)
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Introduction
Pancreatic cancer (PaC) carries a poor prognosis 
since cancer-specific symptoms occur only at an ad-
vanced stage. PaC is associated with a diabetogenic 
state and evidence has emerged that new-onset diabe-
tes mellitus (DM) may be a warning sign necessitating 
further investigation for occult PaC [1, 2]. Improvement 
of diabetes following resection of PaC suggests that dia-
betes is caused by the cancer. Patients with new-onset 
DM have a 5–8-fold increased risk of being diagnosed 
with PaC within 1–3 years of developing diabetes [3]. 
Although the association between new-onset DM and 
PaC is established, the pathogenesis of PaC-associated 
DM is not well understood. It has been postulated that 
PaC-associated DM is a paraneoplastic phenomenon 
caused by diabetogenic tumor-secreted products [4]. 
Recognition of new-onset hyperglycemia as an early 
manifestation of PaC could lead to diagnosis of PaC at 
an early asymptomatic stage. The learning objective of 
the following report is to highlight that new-onset DM 
in the setting of suspicion or risk for PaC may serve as 
a clue that the patient needs further workup for this 
malignancy. 
Case study
A 32-year-old female with no significant past 
medical history presented to us with new onset osmotic 
symptoms and severe hyperglycemia. She underwent a 
routine health check-up outside about 6 months prior 
to her presentation and plasma glucose measured dur-
ing that time was normal. She used to lead a sedentary 
lifestyle. She had been experiencing polydipsia and 
polyuria for preceding 3 weeks associated with blurry 
vision and distal extremity paresthesias. She lost about 
7 kg weight over the last 6 months. Her family history 
was negative for diabetes and or any cancers. Clinical 
examination revealed normal body mass index (BMI) 
(21.5 kg/m2) and absence of acanthosis. Interestingly, 
one of the superficial veins of left upper limb was firm 
and tender on palpation suggestive of thrombophle-
bitis (Fig. 1). Systemic examination was unremarkable. 
Laboratory findings on admission were as follows: 
random blood glucose 408 mg/dL, white blood cell 
count 9,500/μl, bicarbonate 23 mmol/L, anion gap 10, 
and negative serum and urine ketones. Her glycated 
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hemoglobin was 11.7%. Ultrasound of abdomen re-
vealed a heterogeneous mass in the body of pancreas. 
The patient subsequently underwent a CT scan of the 
abdomen with IV contrast that showed a mass (3.2 × 
3.1 × 3.3 cm) extending from the body into the tail of 
the pancreas (Fig. 2). Subsequent laboratory studies 
were significant for an elevated CA 19–9 (349.9 U/mL), 
normal CA-125 (15 U/mL), and a low post-meal 
C-peptide (0.2 ng/mL). CT guided fine needle aspira-
tion of the lesion was performed and was suggestive 
of pancreatic adenocarcinoma. 
Her diabetes was treated with a multiple daily in-
jection (MDI) of  insulin glargine (40 units once daily) 
and insulin aspart 10–20 units three times a day before 
a meal. After discussion with the patient and her family, 
we decided to proceed for surgical resection. However, 
the surgeons found it very difficult to separate the mass 
from the surrounding structures and the mass was 
partly resected and a lateral pancreatico-jejunostomy 
was performed. Histopathology was suggestive of 
pancreatic adenocarcinoma (Fig. 3). The daily insulin 
requirement significantly reduced in the immediate 
post-operative period; however, the patient had a very 
stormy post-operative course which was complicated 
by severe sepsis, respiratory distress syndrome and 
multi-organ failure. Despite our best effort she suc-
cumbed to death on 14th post-operative day.
Discussion
In our patient, new-onset hyperglycemia was a 
harbinger of undetected pancreatic adenocarcinoma. 
Patients with PaC often present with new-onset DM 
which resolves following cancer resection [4]. Unfor-
tunately, in our case a fatal outcome impeded further 
monitoring of glycemic status. Largely, PaC -associated 
diabetes is of recent onset, beginning up to 2 years 
prior the diagnosis of cancer [1]. Weight loss often 
manifests before the development of diabetes. Patel 
et al. reported a middle-aged woman who presented 
with hyperglycemia and was subsequently diagnosed 
with new-onset diabetes and biopsy proven metastatic 
PaC [5]. PaC has a poor prognosis as diagnosis is usually 
made at advanced stages of disease due to delayed 
symptom onset. To substantially impact long-term sur-
vival, early detection of PaC is needed. Evidence from 
studies investigating the association between diabetes 
and PaC suggests that while long-standing diabetes is 
a cause for pancreatic cancer, new-onset diabetes is 
its manifestation [1, 6]. Considering the modest as-
sociation between type 2 DM and PaC, the relatively 
low incidence of PaC, and the fact that type 2 DM is 
rather prevalent in the general population, screening 
all subjects with long-standing diabetes for this cancer 
Figure 1. Superficial thrombophlebitis of one of the upper 
extremity veins (black arrows)
Figure 2. Abdominal CT showing a hetergenously hypodense 
mildly enhancing SOL (3.2 × 3.1 × 3.3 cm) in the body and tail 
region of pancreas. Pancreatic anatomy is grossly disorganized 
and head and neck are not clearly visualized
Figure 3. Photomicrograph showing malignant irregular 
glands haphazardly infiltrating into desmoplastic stroma 
(H and E, × 40).
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will not be cost-effective. Nevertheless, new-onset DM 
secondary to the cancer appears to be a clinically use-
ful sign of occult PaC [1]. New-onset diabetes is found 
in almost 50% of all PaC and several lines of evidence 
suggest that diabetes is attributable to the cancer [7, 
8]. Recent studies have shown that PaC detected at the 
onset of diabetes is usually resectable [8]. Patient with 
newly diagnosed diabetes should have an ultrasound 
of the abdomen. In selected cases where there is clini-
cal suspicion or risk factor of PaC further evaluation 
should be made with assessment of tumor markers like 
CA-19-9 and CEA. Both of these markers have shown 
a positive correlation with PaC-associated diabetes [9].
As in type 2 DM, b-cell dysfunction and peripheral 
insulin resistance are seen in PaC-induced diabetes. 
A low C-peptide level, observed in our case, may indicate 
a possible coexistence of the factors contributing to in-
sulin resistance and decreased insulin secretion (inhibi-
tory factors produced by cancer or cancer-dependent 
immune process). Clinical and laboratory evidence sup-
ports the hypothesis that PaC-associated DM is a para-
neoplastic phenomenon but its biochemical mediator(s) 
are not well-known [4]. One such possible biomarker is 
adrenomedullin, which is a potential mediator of b-cell 
dysfunction in PaC-associated DM [10]. New-onset 
DM provides a high-risk group that could be screened 
for PaC at a time when the cancer is asymptomatic. 
However, the success of the strategy to use new-onset 
DM as a marker of asymptomatic cancer will depend 
the ability to distinguish PaC- associated DM from the 
more common type 2 DM. A clinical distinction between 
PaC-associated diabetes and type 2DM is sometimes 
difficult. Future studies should focus on unraveling the 
pathogenesis and identifying candidate mediator(s) of 
PaC-associated DM to develop discriminating biomark-
ers that can identify PaC-associated DM among subjects 
with new-onset DM. 
To conclude, new-onset hyperglycemia has been 
recognized as a marker of early, asymptomatic PaC. 
In future, new-onset hyperglycemia or diabetes could 
be a potential first sieve for screening of PaC. 
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